Compare MPB & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | CDNA |
|---|---|---|
| Founded | 1868 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 1.0B |
| IPO Year | 1996 | 2007 |
| Metric | MPB | CDNA |
|---|---|---|
| Price | $32.80 | $21.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $37.00 | $28.00 |
| AVG Volume (30 Days) | 116.9K | ★ 773.8K |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $30.95 | $16.01 |
| Revenue Next Year | $9.45 | $11.31 |
| P/E Ratio | ★ $12.73 | $427.30 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $25.83 | $10.96 |
| 52 Week High | $35.22 | $23.24 |
| Indicator | MPB | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 60.44 |
| Support Level | $32.82 | $16.63 |
| Resistance Level | $34.88 | $23.19 |
| Average True Range (ATR) | 0.89 | 1.45 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 29.86 | 71.07 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.